Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation

Metabolism: Clinical and Experimental

Volumn 57, Issue 5, 2008, Pages 593-597

  Canibus, Paola ^a   Faloia, Emanuela ^a   Piva, Tommaso ^b   Muçai, Andi ^b   Serenelli, Massimiliano ^b   Perna, Gian Piero ^b   Boscaro, Marco ^a   Piva, Roberto ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Monospecialistico Cardiologico GM Lancisi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 42949172862     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.10.020     Document Type: Article

References (30)

1. Muggeo M., and Bonora E. Diabete e sindrome plurimetabolica (2001), Pacini Editore, Pisa
2. National Institute of Health. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III) (2001), National Institute of Health, Bethesda (Md) NIH Publication 01-3670
3. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
4. Cameron A.J., Shaw J.E., Zimmet P.Z., et al. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33 (2004) 351-375
5. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., Pyorala K., and DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164 (2004) 1066-1076
6. Bonora E., Kiechl S., Willeit J., et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord. 27 (2003) 1283-1289
7. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Heart and Nutrition Examination Survey. JAMA 287 (2002) 356-359
8. Miccoli R., Bianchi C., Odoguardi L., et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 15 (2005) 250-254
9. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
10. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total cardiovascular disease mortality in middle aged men. JAMA 288 (2002) 2709-2716
11. Isomaa B., Henricsson M., Almgren P., et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44 (2001) 1148-1154
12. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 92 (2007) 399-404
13. Rana J.S., Monraats P.S., Zwinderman A.H., et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care 28 (2005) 873-877
14. Kip K.E., Alderman E.L., Bourassa M.G., et al. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery. Bypass Angioplasty Revascularization Investigation. Circulation 105 (2002) 1914-1920
15. Aronson D., Bloomgarden Z., Rayfield E.J., et al. Potential mechanism promoting restenosis in diabetic patients. J Am Coll Cardiol 27 (1996) 528-535
16. Takagi T., Akasaka T., Yamamuro A., et al. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation: intravascular ultrasound study. J Diabetes Complication 16 (2002) 50-55
17. Regar E., Serruyis P.W., Bode C., et al. Angiographic findings of the multicenter Randomized Study with the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106 (2002) 1949-1956
18. Moussa I., Leon M.B., Baim D., et al. Impact of sirolimus-eluting stent on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesion) substudy. Circulation 109 (2004) 2273-2278
19. Lotan C., Sousa E., Urban P., et al. Sirolimus-eluting stent implantation in routine clinical practice: a 12-month follow-up report from the international e-CYPHER registry. J Am Coll Cardiol 43 (2004) 97A
20. Stone G.W., Ellis S.G., Cox D.A., et al., for the TAXUS-IV Investigators. . One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
21. Lean M.E., Han T.S., Morrison C.E., et al. Waist circumference as a measure for indicating need for weight management. BMJ 311 (1995) 158-161
22. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
23. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal. Diabetes Care 28 (2005) 2289-2304
24. Hoffman R., Mintz G.S., Dussaillant G.R., et al. Patterns and mechanism of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94 (1996) 1247-1254
25. Takagi T., Yoshida K., Akasaka T., et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients. A serial intravascular ultrasound study. J Am Coll Cardiol. 36 (2000) 731-738
26. Piatti P.M., Di Mario C., Monti L.D., et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108 (2003) 2074-2081
27. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med. 356 (2007) 325-328
28. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
29. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 356 (2007) 989-997
30. Nikolsky E., Kosinski E., Mishkel G.J., et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol 95 (2005) 709-715